

Basel, 21 July 2016

Roche delivers continued growth in the first half of 2016

- Group sales increased by 5%¹ at constant exchange rates, 6% in Swiss francs
- Pharmaceuticals Division sales up 4%, driven by oncology and immunology medicines
- Diagnostics Division sales grew 6%, driven primarily by immunodiagnostic products; challenging market conditions in Diabetes Care
- Core earnings per share grew slightly faster than sales at 5% at constant exchange rates, 7% in Swiss francs
- OCREVUS filed in US and EU for relapsing and primary progressive forms of multiple sclerosis; FDA granted priority review
- Cancer immunotherapy medicine Tecentriq received accelerated FDA approval in bladder cancer in the US
- cobas e801 immunodiagnostic module launched for high-volume testing
- Outlook for 2016 confirmed

Key figures January - June	In millions of CHF		% change	
	2016	2015	CER ¹	CHF
Group sales	25,022	23,585	+5	+6
Pharmaceuticals Division	19,460	18,350	+4	+6
Diagnostics Division	5,562	5,235	+6	+6
Core operating profit	9,854	9,236	+5	+7
Core EPS - diluted (CHF)	7.74	7.22	+5	+7
IFRS net income	5,467	5,249	+3	+4

Commenting on the Group's results, Roche CEO Severin Schwan said: "In the first half of the year, both our Pharmaceuticals and Diagnostics Divisions showed good growth across all regions. The launch of our first cancer immunotherapy medicine Tecentriq is off to a strong start. We also completed the US and EU filings of OCREVUS, which brings us an important step closer toward launching this promising multiple sclerosis medicine. Based on our half year performance, I am confident that we will meet our full-year targets for 2016."

¹ Unless otherwise stated, all growth rates in this document are at constant exchange rates (CER: average 2015).

Group

Strong performance in both divisions

In the first half of 2016, Group sales rose 4.8% at constant exchange rates to CHF 25.0 billion. Core EPS grew 5.2% at constant exchange rates, slightly faster than sales. Core EPS growth reflects the good underlying business performance, investments into the launch of new products and the product pipeline, the one-off accounting impact of changes to the Group's Swiss pension plans, as well as an early bond redemption.

IFRS net income was up 3% at constant exchange rates and 4% in Swiss francs. The positive currency effect was driven by the weakening of the Swiss franc against the US dollar, the yen and the euro, partly offset by a strengthening of Latin American currencies.

Sales in the Pharmaceuticals Division were up 4% to CHF 19.5 billion, driven by demand for oncology and immunology medicines. Sales in the US increased 4%, led by immunology treatments Xolair and Esbriet, as well as Herceptin and Perjeta against HER2-positive breast cancer. There was high demand for Alecensa, which was recently launched in the US for a specific type of lung cancer. Sales of Lucentis and Tarceva declined due to the continued impact of competition. In Europe (+5%), Perjeta, MabThera/Rituxan and Actemra/RoActemra recorded strong sales growth, especially in Germany and France. In the International region (+4%), growth was driven by HER2 medicines, Avastin and MabThera/Rituxan. This growth was partly offset by lower Pegasys sales due to competition from a new generation of hepatitis C treatments. In Japan, sales rose 2% driven by HER2 medicines, Alecensa and Actemra/RoActemra.

Sales in the Diagnostics Division grew 6% to CHF 5.6 billion. All regions contributed to this growth, particularly Asia-Pacific (+17%). Professional and Tissue Diagnostics grew strongly. Diabetes Care sales were impacted by continued challenging market conditions, especially in North America.

Regulatory approvals

In the second quarter, Roche achieved several key regulatory milestones. In April, Venclexta (venetoclax) received accelerated approval in the US for a specific form of leukemia. This medicine was jointly developed with AbbVie. In May, the FDA granted cancer immunotherapy Tecentriq (atezolizumab) accelerated approval in the US for a specific type of bladder cancer. Also in May, the subcutaneous formulation of MabThera/Rituxan received approval in the EU for people with chronic lymphocytic leukaemia. In June, the European Commission approved Gazyva/Gazyvaro plus bendamustine for the second-line treatment of follicular lymphoma. The EU authorities also approved the combination of Avastin and Tarceva for the treatment of people with a specific type of lung cancer.

Strong Pharma pipeline

Roche made significant progress in late-stage development. In June, the European Medicines Agency (EMA) and the FDA confirmed that the data submission for OCREVUS (ocrelizumab) is complete, and the marketing applications for both relapsing and progressive multiple sclerosis are being reviewed. In addition, the FDA granted priority review for the US application with an action date of 28 December 2016.

In the same month, the largest clinical trial ever conducted in giant cell arteritis (GCA), a serious inflammatory disease of blood vessels, showed positive results. Initially combined with a six-month steroid regimen, Actemra/RoActemra more effectively sustained remission through one year compared to a 6- or 12-month steroid-only regimen in people with newly diagnosed and relapsing GCA.

At the American Society of Clinical Oncology (ASCO) annual meeting in June, Roche presented an updated clinical analysis for Tecentriq in previously treated lung cancer. Overall survival benefit was seen regardless of Programmed Death-Ligand 1 (PD-L1) expression compared to chemotherapy. In addition, Roche shared encouraging results from clinical trials with Tecentriq in combination with chemotherapy, targeted anti-cancer medicines and other cancer immunotherapy agents in several tumour types.

In May, a phase III study (J-ALEX) by Chugai found that Alecensa significantly reduced the risk of disease worsening or death compared to crizotinib. This trial in a Japanese patient population with advanced or recurrent ALK-positive non-small cell lung cancer was stopped early after a pre-planned interim analysis.

Roche recently provided an update on the phase III study of Gazyva/Gazyvaro in previously untreated diffuse large B-cell lymphoma (GOYA). The study did not meet its primary goal of extending the time patients live without their disease advancing. In May, another phase III study of Gazyva/Gazyvaro (GALLIUM) was stopped early after a pre-planned interim analysis showed positive results in the first-line treatment of follicular lymphoma. In both studies, Gazyva/Gazyvaro plus chemotherapy was tested head-to-head with MabThera/Rituxan combined with chemotherapy. The GALLIUM data will be submitted to health authorities for approval consideration. Gazyva/Gazyvaro is already approved for previously treated follicular lymphoma.

Portfolio progress in Diagnostics

In May, Roche launched the CoaguChek INRange, the first Bluetooth enabled home device, allowing patients and their healthcare providers greater control over their coagulation status. In June, Roche launched the cobas e801 module in countries accepting the CE Mark. As part of the cobas 8000 analyzer, this module provides increased immunochemistry testing capacity and an extensive test menu to laboratories with high testing volumes. Also in June, the cobas liquid biopsy test for the detection of specific mutations of the epidermal growth factor receptor (EGFR) gene became the first FDA approved liquid biopsy test. It can support therapy

guidance in non-small cell lung cancer (NSCLC) via the analysis of a simple blood sample; and it complements the existing tissue-based EGFR test.

Outlook for 2016 confirmed

Roche continues to expect sales to grow low- to mid-single digit at constant exchange rates in 2016. Core earnings per share are targeted to grow ahead of sales at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

Pharmaceuticals Division

Key figures January – June	In millions of CHF		As % of sales		% change	
	2016	2015	2016	2015	At CER	In CHF
Pharmaceuticals Division	19,460	18,350	100	100	+4	+6
United States	9,273	8,586	48	47	+4	+8
Europe	4,639	4,291	24	23	+5	+8
Japan	1,756	1,540	9	8	+2	+14
International*	3,792	3,933	19	22	+4	-4

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

Herceptin, Perjeta and Kadcyla (combined +10%). For HER2-positive breast cancer and HER2-positive metastatic gastric cancer (Herceptin only). **Herceptin** sales grew 5%, driven by increasing demand in the US due to longer duration of treatment in combination with Perjeta and in China following improved access. **Perjeta** (+34%) performed well, particularly in Europe and the US driven mainly by uptake in the neoadjuvant setting and continued strong growth in the metastatic setting. **Kadcyla** sales (+11%) grew mainly because of increasing demand in the International region and in Europe. Kadcyla is approved as a single agent in more than 80 countries worldwide for the second-line treatment of HER2-positive metastatic breast cancer.

MabThera/Rituxan (+4%). For common forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Sales continued to grow, despite competitive pressure, with increasing demand in the US, Europe and the International region. The use of the subcutaneous formulation of MabThera/Rituxan has been expanding globally, with a recent launch in Brazil.

Avastin (+4%). For advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, and relapsed glioblastoma (a type of brain tumour). Sales continued to grow and were driven by the International region (+22%), especially China, where sales increased following improved access in the lung cancer setting. In Europe, sales grew 3% as a result of increasing use in breast and colorectal cancer, in particular in Germany. Sales in the US, where Avastin already is being broadly used in its approved indications, declined 1%. In Japan, sales grew 2%, with increasing growth in all approved indications outweighing the impact of bi-annual government-mandated price cuts that took effect in April.

Gazyva/Gazyvaro (+42%). For the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma. Strong growth was seen in the US and Europe despite increasing competition in CLL. Gazyva/Gazyvaro is now approved for CLL in more than 70 countries. In addition to FDA approval in February, in June this medicine was also approved in Europe for people with previously treated follicular lymphoma. The initial uptake for this indication in the US has been encouraging.

Actemra/RoActemra (+17%). For rheumatoid arthritis and forms of juvenile idiopathic arthritis. Increasing use of Actemra/RoActemra as a single agent, and of the subcutaneous formulation, remained key growth drivers in the US and Europe.

Esbriet (+51%). For idiopathic pulmonary fibrosis (IPF). This medicine experienced continued good market uptake. Sales reached CHF 261 million in the US and CHF 86 million in Europe.

All newly launched medicines also showed good sales performance. In December 2015, **Alecensa** received approval in the US for the treatment of people with ALK-positive advanced non-small cell lung cancer whose disease has progressed on, or who are intolerant to crizotinib. It has had strong uptake there, driven by use in the second- and third-line treatment settings. In Japan, where Alecensa was first launched in 2014 for unresectable, recurrent or advanced ALK-positive NSCLC, sales continued to grow strongly. Also late in 2015, Roche received approvals in the US and EU for **Cotellic** in combination with Zelboraf to treat metastatic melanoma. Cotellic had a good start, especially in France, Germany and the US. Following the accelerated approval of **Tecentriq** in locally advanced or metastatic urothelial carcinoma in the US in May, the initial market uptake has been very good.

Top-selling Pharmaceuticals January – June	Total		United States		Europe		Japan		International*	
	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
MabThera/Rituxan	3,702	4	2,001	3	961	5	134	12	606	7
Herceptin	3,434	5	1,281	5	1,048	2	146	5	959	7
Avastin	3,430	4	1,538	-1	944	3	398	2	550	22
Perjeta	906	34	454	16	310	60	50	14	92	91
Actemra/RoActemra	814	17	309	18	274	19	130	14	101	16
Xolair	731	19	731	19	-	-	-	-	-	-
Lucentis	704	-12	704	-12	-	-	-	-	-	-
Activase/TNKase	537	19	515	19	-	-	-	-	22	8
Tarceva	520	-16	277	-16	92	-22	49	2	102	-15
Tamiflu	410	-5	263	-18	31	152	64	8	52	25

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

Diagnosics Division

Key figures January - June		In millions of CHF	% change		As % of sales
			At CER	In CHF	
Sales - Diagnostics Division		5,562	+6	+6	100
Business Areas	Professional Diagnostics	3,233	+9	+9	58
	Diabetes Care	998	-4	-6	18
	Molecular Diagnostics	903	+8	+9	16
	Tissue Diagnostics	428	+12	+14	8
Regions	Europe, Middle East, Africa	2,314	+1	+2	42
	North America	1,466	+2	+5	26
	Asia-Pacific	1,192	+17	+15	21
	Latin America	375	+27	+6	7
	Japan	215	+2	+14	4

Professional Diagnostics (+9%) was the largest contributor to the Division's sales performance, led by the Asia-Pacific region, with continued strong growth in China (+25%). The immunodiagnosics business saw strong growth (+14%) and sales of the clinical chemistry business increased 6%.

In May, the CoaguChek INRange was introduced in countries accepting the CE Mark. The CoaguChek INRange system is the first Bluetooth enabled PT/INR² home health device that helps patients and their healthcare providers have greater control over their coagulation status and the ability to monitor Vitamin K Antagonist therapy.

In June, the cobas e801 module was launched in markets accepting the CE Mark. This is a high-volume immunochemistry analyser which offers laboratories a significant gain in productivity and efficiency.

In **Molecular Diagnostics**, sales increased 8%, led by the Asia-Pacific region. The main growth contributors were the sequencing and molecular businesses. The molecular business growth was driven by virology (+12%) including the diagnosis and monitoring of hepatitis and HIV viral load as well as HPV screening (+16%).

In April, a new collaboration was announced to increase access to testing and treatment for people infected with the hepatitis C virus in six low- and middle-income countries. Additional members of the collaboration include the Clinton Health Access Initiative Inc., USA, and Ministries of Health in Ethiopia, Indonesia, Myanmar, Nigeria, Rwanda and Vietnam.

² PT/INR: Prothrombin Time and International Normalized Ratio

In June, the FDA approved the cobas EGFR Mutation Test v2 as a companion diagnostic for Tarceva in non-small cell lung cancer in the US. This test is the first FDA approved assay for a liquid biopsy indication and can use both plasma and tumour tissue for detection of the epidermal growth factor receptor gene.

Also in June, the availability of the LightMix Modular Zika Virus Assay in markets accepting the CE Mark was announced. This diagnostic test can be used on the LightCycler 480 system to analyse blood samples from patients with signs and symptoms of Zika virus infection. This follows an FDA announcement in March allowing the use of an investigational Roche test to screen blood donations for the Zika virus.

Tissue Diagnostics sales increased 12%, driven by sales in North America. Sales in the advanced staining portfolio grew 9% and sales in primary staining increased 16%. The strong increase in primary staining was driven by the new, fully automated Ventana HE 600 system for hematoxylin and eosin tissue staining, launched in late 2015. Revenue from external personalised healthcare partnerships showed continued strong growth (+29%).

In May, the FDA approved the Ventana PD-L1 (SP142) test as a complementary diagnostic for Tecentriq treatment. This test measures levels of PD-L1 expression in patients with bladder cancer.

Diabetes Care sales decreased 4%, predominantly due to continued price pressure in the US. Increasing sales were recorded in Latin America, while EMEA and Asia-Pacific regional sales were down.

Half Year Results 2016 – Live video webcast and conference call

There will be a live video webcast and conference call for investors and analysts today, **Thursday, 21 July at 1:00 pm CEST**.

To access the **live video webcast**, please click [here](#) and access the webcast under "Current Events".

To listen to the **conference call**, please dial in to the conference 10-15 min prior to the scheduled start, using the following numbers:

+41 (0) 58 310 5000 (Europe and ROW)

+44 (0) 203 059 5862 (UK)

+1 (1) 631 570 5613 (USA Toll Free)

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in

in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Additional information

- Q2 2016 Presentation: <http://www.roche.com/irp160721-a.pdf>
- Q2 2016 Presentation with appendix: <http://www.roche.com/irp160721.pdf>
- Pharmaceuticals: major clinical and regulatory news-flow in 2016: <http://www.roche.com/pharmaHY16.pdf>
- Diagnostics: key diagnostics product launches in 2016: <http://www.roche.com/diaHY16.pdf>
- Finance Report Half Year 2016: www.roche.com/annual_reports
- Roche Annual Report 2015 (includes corporate responsibility report): www.roche.com/annual_reports
- Dow Jones Sustainability Indices: <http://www.sustainability-indices.com>

Roche Investor Relations

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Tamer Farhan

Phone: +41 61 68-82552

e-mail: tamer.farhan@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Neera Dahiya Ravindran, MD

Phone: +1 650 491 5281

e-mail: ravindran.neera@gene.com

Nina Goworek

Phone: +1 650 467 8737

e-mail: goworek.nina@gene.com

Disclaimer: Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for 2015 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Appendix: Tables

1.	Sales January to June 2016 and 2015	11
2.	Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015	12
3.	Pharmaceuticals Division – Top-selling pharmaceuticals and recent new launches	13
4.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2016 vs. HY 2015	14
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	15
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	16
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	17
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	18
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*	19
10.	Roche Group consolidated income statement for the six months ended 30 June 2016	20
11.	Roche Group core results reconciliation – Half Year 2016	21
12.	Divisional core results reconciliation – Half Year 2016	22
13.	Roche Group consolidated balance sheet	23
14.	Roche Group consolidated statement of cash flows	24

1. Sales January to June 2016 and 2015

CHF millions	Six months ended 30 June		% change	
	2016	2015	At CER	In CHF
Pharmaceuticals Division	19,460	18,350	4	6
United States	9,273	8,586	4	8
Europe	4,639	4,291	5	8
Japan	1,756	1,540	2	14
International*	3,792	3,933	4	-4
Diagnostics Division	5,562	5,235	6	6
Roche Group	25,022	23,585	5	6

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
Pharmaceuticals Division	9,028	7	9,340	6	9,641	3	9,800	4	9,660	5
United States	4,194	7	4,461	7	4,569	3	4,716	3	4,557	5
Europe	2,113	3	2,185	6	2,258	5	2,319	5	2,320	6
Japan	777	18	801	8	883	2	853	4	903	1
International*	1,944	5	1,893	4	1,931	2	1,912	4	1,880	5
Diagnostics Division	2,724	7	2,600	4	2,979	7	2,614	5	2,948	8
Roche Group	11,752	7	11,940	6	12,620	4	12,414	4	12,608	6

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division – Top-selling pharmaceuticals and recent new launches

Top-selling pharmaceuticals and recent new launches	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
January - June 2016										
MabThera/Rituxan	3,702	4	2,001	3	961	5	134	12	606	7
Herceptin	3,434	5	1,281	5	1,048	2	146	5	959	7
Avastin	3,430	4	1,538	-1	944	3	398	2	550	22
Perjeta	906	34	454	16	310	60	50	14	92	91
Actemra/RoActemra	814	17	309	18	274	19	130	14	101	16
Xolair	731	19	731	19	-	-	-	-	-	-
Lucentis	704	-12	704	-12	-	-	-	-	-	-
Activase/TNKase	537	19	515	19	-	-	-	-	22	8
Tarceva	520	-16	277	-16	92	-22	49	2	102	-15
Tamiflu	410	-5	263	-18	31	152	64	8	52	25
Recent new launches										
Esbriet	358	51	261	70	86	22	-	-	11	-2
Zelboraf	110	4	23	-1	66	4	2	63	19	7
Erivedge	99	35	66	26	25	51	-	-	8	66
Gazyva	91	42	58	62	23	157	-	-	10	-46
Alecensa	72	176	26	-	-	-	46	71	-	-
Tecentriq	19	-	19	-	-	-	-	-	-	-
Cotellic	19	-	5	-	14	-	-	-	-	-

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth HY 2016 vs. HY 2015

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	3,702	4	2,001	3	961	5	134	12	606	7
Herceptin	3,434	5	1,281	5	1,048	2	146	5	959	7
Avastin	3,430	4	1,538	-1	944	3	398	2	550	22
Perjeta	906	34	454	16	310	60	50	14	92	91
Actemra/RoActemra	814	17	309	18	274	19	130	14	101	16
Xolair	731	19	731	19	-	-	-	-	-	-
Lucentis	704	-12	704	-12	-	-	-	-	-	-
Activase/TNKase	537	19	515	19	-	-	-	-	22	8
Tarceva	520	-16	277	-16	92	-22	49	2	102	-15
Tamiflu	410	-5	263	-18	31	152	64	8	52	25
Kadcyla	408	11	159	2	167	7	37	23	45	54
CellCept	373	-5	88	-10	89	-1	33	13	163	-6
Esbriet	358	51	261	70	86	22	-	-	11	-2
Pulmozyme	337	9	233	6	61	5	-	-	43	32
Mircera	241	4	-	-	43	-4	100	3	98	8
Xeloda	230	-12	17	-47	17	-25	54	14	142	-10
NeoRecormon/Epogin	161	-11	-	-	71	-10	22	-12	68	-12
Valcyte/Cymevene	160	-14	38	-8	60	-24	-	-	62	-6
Rocephin	157	11	-	-	20	-13	13	-15	124	20
Pegasys	143	-49	21	-18	36	-37	2	-80	84	-55

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
MabThera/Rituxan	1,752	6	1,772	4	1,777	4	1,825	3	1,877	5
Herceptin	1,613	10	1,614	7	1,659	10	1,725	4	1,709	5
Avastin	1,644	13	1,705	8	1,716	9	1,706	4	1,724	4
Perjeta	337	64	376	57	410	50	439	33	467	35
Actemra/RoActemra	341	23	367	18	390	25	386	14	428	21
Xolair	312	27	339	21	345	22	356	22	375	17
Lucentis	375	-16	373	-18	378	-17	355	-13	349	-10
Activase/TNKase	216	16	239	14	259	36	276	21	261	17
Tarceva	307	-10	292	-7	287	-9	258	-14	262	-17
Tamiflu	41	61	118	46	170	-67	367	-6	43	5
Kadcyla	183	54	196	44	211	36	201	11	207	10
CellCept	191	-1	194	-4	203	13	189	-4	184	-5
Esbriet	141	-	157	-	177	296	178	96	180	24
Pulmozyme	160	15	166	14	180	8	160	7	177	10
Mircera	108	17	147	55	106	-1	118	0	123	7
Xeloda	124	-29	124	-11	129	-9	111	-17	119	-5
NeoRecormon/Epogin	89	-19	90	-8	94	-6	79	-14	82	-8
Valcyte/Cymevene	87	-47	83	-52	99	-41	78	-21	82	-6
Rocephin	63	0	64	-8	73	-1	82	5	75	18
Pegasys	117	-58	120	-45	133	-32	82	-50	61	-48

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
MabThera/Rituxan	938	7	947	4	938	7	978	0	1,023	6
Herceptin	578	18	609	12	599	13	651	4	630	6
Avastin	741	11	784	6	772	11	775	-2	763	0
Perjeta	192	43	208	37	217	31	224	15	230	16
Actemra/RoActemra	129	30	144	21	153	32	145	12	164	23
Xolair	312	27	339	21	345	22	356	22	375	17
Lucentis	375	-16	373	-18	378	-17	355	-13	349	-10
Activase/TNKase	206	18	228	15	246	36	265	21	250	18
Tarceva	165	-15	159	-7	160	1	136	-15	141	-17
Tamiflu	24	131	104	54	121	-74	251	-15	12	-45
Kadcyla	72	-2	79	6	79	12	79	-2	80	7
CellCept	51	2	53	-14	54	29	45	0	43	-18
Esbriet	98	-	114	-	124	*	127	145	134	32
Pulmozyme	109	15	115	9	128	19	112	6	121	7
Mircera	-	-	-	-	-	-	-	-	-	-
Xeloda	16	-48	12	3	13	13	5	-71	12	-24
NeoRecormon/Epogin	-	-	-	-	-	-	-	-	-	-
Valcyte/Cymevene	16	-83	16	-86	33	-64	19	-25	19	15
Rocephin	-	-	-	-	-	-	-	-	-	-
Pegasys	13	-84	17	-45	43	74	11	-16	10	-20

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
MabThera/Rituxan	443	-1	455	1	468	3	479	5	482	5
Herceptin	490	-1	502	0	510	4	525	2	523	3
Avastin	435	4	457	5	465	5	471	2	473	4
Perjeta	99	125	114	96	130	74	149	65	161	56
Actemra/RoActemra	114	21	120	19	129	23	131	17	143	21
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	56	-16	54	-20	52	-23	48	-18	44	-27
Tamiflu	1	478	1	-65	3	455	20	78	11	*
Kadcyla	79	135	83	92	88	49	83	13	84	2
CellCept	43	-9	44	-10	47	-1	43	-3	46	2
Esbriet	37	-	37	-	46	44	45	36	41	9
Pulmozyme	28	2	29	8	30	8	31	6	30	5
Mircera	22	-3	21	-1	22	-4	21	-7	22	-2
Xeloda	9	-53	10	-41	10	-30	9	-31	8	-17
NeoRecormon/Epogin	38	-11	38	-9	38	-6	36	-10	35	-11
Valcyte/Cymevene	37	-8	39	-1	36	-16	30	-26	30	-21
Rocephin	8	-8	5	-15	9	-27	13	-13	7	-13
Pegasys	24	-58	24	-45	22	-45	19	-40	17	-33

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
MabThera/Rituxan	55	28	59	7	64	9	62	12	72	12
Herceptin	65	22	65	3	70	3	67	5	79	4
Avastin	182	29	189	13	208	12	192	7	206	-2
Perjeta	21	21	22	18	23	14	23	18	27	10
Actemra/RoActemra	54	28	57	13	61	10	60	14	70	13
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	23	8	25	12	24	-1	22	0	27	3
Tamiflu	-1	-97	-	-	12	-75	60	4	4	*
Kadcyla	15	81	15	39	16	23	17	27	20	20
CellCept	14	8	14	11	16	11	15	11	18	16
Esbriet	-	-	-	-	-	-	-	-	-	-
Pulmozyme	-	-	-	-	-	-	-	-	-	-
Mircera	47	23	48	6	54	9	45	4	55	2
Xeloda	22	22	22	8	25	10	25	12	29	16
NeoRecormon/Epogin	12	0	12	-7	12	-9	10	-12	12	-12
Valcyte/Cymevene	-	-	-	-	-	-	-	-	-	-
Rocephin	7	1	8	-2	7	-5	6	-10	7	-19
Pegasys	5	-73	2	-82	2	-84	1	-83	1	-76

* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q2 2015	% change vs. Q2 2014	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015
MabThera/Rituxan	316	13	311	5	307	-2	306	11	300	3
Herceptin	480	14	438	9	480	16	482	7	477	8
Avastin	286	27	275	16	271	7	268	27	282	18
Perjeta	25	112	32	125	40	131	43	65	49	121
Actemra/RoActemra	44	8	46	15	47	31	50	10	51	23
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	10	-10	11	-11	13	32	11	13	11	3
Tarceva	63	6	54	-1	51	-18	52	-14	50	-15
Tamiflu	17	18	13	22	34	73	36	35	16	9
Kadcyla	17	131	19	74	28	93	22	56	23	53
CellCept	83	1	83	5	86	16	86	-8	77	-4
Esbriet	6	-	6	-	7	114	6	4	5	-8
Pulmozyme	23	34	22	49	22	-22	17	22	26	38
Mircera	39	24	78	206	30	-13	52	0	46	18
Xeloda	77	-27	80	-11	81	-12	72	-13	70	-6
NeoRecormon/Epogin	39	-29	40	-8	44	-5	33	-18	35	-5
Valcyte/Cymevene	34	-1	28	-17	30	-22	29	-14	33	2
Rocephin	48	2	51	-7	57	0	63	12	61	30
Pegasys	75	-42	77	-40	66	-42	51	-55	33	-56

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

10. Roche Group consolidated income statement for the six months ended 30 June 2016

in millions of CHF

	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	19,460	5,562	0	25,022
Royalties and other operating income	926	60	0	986
Cost of sales	(4,809)	(2,769)	0	(7,578)
Marketing and distribution	(3,048)	(1,314)	0	(4,362)
Research and development	(4,619)	(678)	0	(5,297)
General and administration	(279)	(197)	(153)	(629)
Operating profit	7,631	664	(153)	8,142
Financing costs				(600)
Other financial income (expense)				(23)
Profit before taxes				7,519
Income taxes				(2,052)
Net income				5,467
Attributable to				
- Roche shareholders				5,378
- Non-controlling interests				89
Earnings per share and non-voting equity security				
Basic (CHF)				6.31
Diluted (CHF)				6.24

11. Roche Group core results reconciliation – Half Year 2016

in millions of
CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Alliances & business combinations	Legal & environmental	Normalisation of ECP tax benefit	Core
Sales	25,022	-	-	-	-	-	-	25,022
Royalties and other operating income	986	-	-	-	-	-	-	986
Cost of sales	(7,578)	161	823	-	166	-	-	(6,428)
Marketing and distribution	(4,362)	51	2	-	-	-	-	(4,309)
Research and development	(5,297)	69	71	377	-	-	-	(4,780)
General and administration	(629)	110	-	-	(145)	27	-	(637)
Operating profit	8,142	391	896	377	21	27	-	9,854
Financing costs	(600)	1	-	-	21	5	-	(573)
Other financial income (expense)	(23)	-	-	-	-	-	-	(23)
Profit before taxes	7,519	392	896	377	42	32	-	9,258
Income taxes	(2,052)	(75)	(299)	(93)	(38)	(11)	71	(2,497)
Net income	5,467	317	597	284	4	21	71	6,761
Attributable to								
- Roche shareholders	5,378	316	590	284	4	21	70	6,663
- Non-controlling interests	89	1	7	-	-	-	1	98
EPS - diluted (CHF)	6.24	0.37	0.69	0.33	-	0.03	0.08	7.74

12. Divisional core results reconciliation – Half Year 2016

in millions of CHF							
	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Alliances & business combinations	Legal & environmental	Core
Pharmaceuticals							
Sales	19,460	-	-	-	-	-	19,460
Royalties and other operating income	926	-	-	-	-	-	926
Cost of sales	(4,809)	121	654	-	166	-	(3,868)
Marketing and distribution	(3,048)	8	1	-	-	-	(3,039)
Research and development	(4,619)	45	68	377	-	-	(4,129)
General and administration	(279)	61	-	-	(152)	4	(366)
Operating profit	7,631	235	723	377	14	4	8,984
Diagnostics							
Sales	5,562	-	-	-	-	-	5,562
Royalties and other operating income	60	-	-	-	-	-	60
Cost of sales	(2,769)	40	169	-	-	-	(2,560)
Marketing and distribution	(1,314)	43	1	-	-	-	(1,270)
Research and development	(678)	24	3	-	-	-	(651)
General and administration	(197)	34	-	-	6	23	(134)
Operating profit	664	141	173	-	6	23	1,007
Corporate							
General and administration	(153)	15	-	-	1	-	(137)
Operating profit	(153)	15	-	-	1	-	(137)

13. Roche Group consolidated balance sheet

in millions of CHF	30 June 2016	31 December 2015	31 December 2014
Non-current assets			
Property, plant and equipment	19,090	18,473	17,195
Goodwill	11,030	11,082	9,930
Intangible assets	12,877	13,861	12,799
Deferred tax assets	2,958	2,564	2,829
Defined benefit plan assets	710	642	691
Other non-current assets	1,237	959	982
Total non-current assets	47,902	47,581	44,426
Current assets			
Inventories	8,221	7,648	7,743
Accounts receivable	9,104	8,329	9,003
Current income tax assets	262	239	244
Other current assets	2,484	2,795	2,421
Marketable securities	3,724	5,440	7,961
Cash and cash equivalents	2,817	3,731	3,742
Total current assets	26,612	28,182	31,114
Total assets	74,514	75,763	75,540
Non-current liabilities			
Long-term debt	(16,415)	(17,100)	(19,347)
Net deferred tax liabilities	(252)	(545)	(504)
Defined benefit plan liabilities	(9,751)	(8,341)	(8,994)
Provisions	(2,037)	(2,204)	(1,778)
Other non-current liabilities	(522)	(505)	(251)
Total non-current liabilities	(28,977)	(28,695)	(30,874)
Current liabilities			
Short-term debt	(8,399)	(6,151)	(6,367)
Current income tax liabilities	(3,333)	(2,781)	(2,616)
Provisions	(2,261)	(2,432)	(2,465)
Accounts payable	(2,495)	(3,207)	(2,883)
Other current liabilities	(7,968)	(9,197)	(8,777)
Total current liabilities	(24,456)	(23,768)	(23,108)
Total liabilities	(53,433)	(52,463)	(53,982)
Total net assets	21,081	23,300	21,558
Equity			
Capital and reserves attributable to Roche shareholders	18,458	20,979	19,586
Equity attributable to non-controlling interests	2,623	2,321	1,972
Total equity	21,081	23,300	21,558

14. Roche Group consolidated statement of cash flows

in millions of CHF

	HY 2016	HY 2015
Cash flows from operating activities		
Cash generated from operations	11,005	10,917
(Increase) decrease in net working capital	(2,776)	(1,764)
Payments made for defined benefit plans	(429)	(312)
Utilisation of provisions	(432)	(473)
Disposal of products	50	45
Other operating cash flows	-	-
Cash flows from operating activities, before income taxes paid	7,418	8,413
Income taxes paid	(1,748)	(1,846)
Total cash flows from operating activities	5,670	6,567
Cash flows from investing activities		
Purchase of property, plant and equipment	(1,736)	(1,614)
Purchase of intangible assets	(380)	(334)
Disposal of property, plant and equipment	29	21
Disposal of intangible assets	-	-
Business combinations	(69)	(1,402)
Divestment of subsidiaries	-	-
Interest and dividends received	13	15
Sales of marketable securities	22,822	30,505
Purchases of marketable securities	(20,895)	(26,475)
Other investing cash flows	(194)	(20)
Total cash flows from investing activities	(410)	696
Cash flows from financing activities		
Proceeds from issue of bonds and notes	1,690	1,670
Redemption and repurchase of bonds and notes	(2,943)	(1,379)
Increase (decrease) in commercial paper	2,854	(86)
Increase (decrease) in other debt	(68)	98
Hedging and collateral arrangements	51	(163)
Changes in non-controlling interests	-	(2)
Equity contribution by non-controlling interests - capital injection	-	40
Interest paid	(601)	(681)
Dividends paid	(6,969)	(6,894)
Equity-settled equity compensation plans, net of transactions in own equity	(289)	(77)
Other financing cash flows	(1)	1
Total cash flows from financing activities	(6,276)	(7,473)
Net effect of currency translation on cash and cash equivalents	102	(285)
Increase (decrease) in cash and cash equivalents	(914)	(495)
Cash and cash equivalents at beginning of period	3,731	3,742
Cash and cash equivalents at end of period	2,817	3,247